Celldex Therapeutics Inc
CLDX24.370USD
+1.700+7.50%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.62BMarket Cap
LossP/E TTM
More Details of Celldex Therapeutics Inc Company
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Celldex Therapeutics Inc Info
Ticker SymbolCLDX
Company nameCelldex Therapeutics Inc
IPO dateMay 15, 1986
CEOMr. Anthony S. Marucci
Number of employees186
Security typeOrdinary Share
Fiscal year-endMay 15
Address53 Frontage Road
CityHAMPTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08827
Phone19084547120
Websitehttps://celldex.com/
Ticker SymbolCLDX
IPO dateMay 15, 1986
CEOMr. Anthony S. Marucci
Company Executives of Celldex Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
33.37K
-2.26%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Mr. Herbert J. (Herb) Conrad
Mr. Herbert J. (Herb) Conrad
Independent Director
Independent Director
2.56K
--
Mr. James J. (Jim) Marino
Mr. James J. (Jim) Marino
Independent Director
Independent Director
2.20K
--
Mr. Keith L. Brownlie, CPA
Mr. Keith L. Brownlie, CPA
Independent Director
Independent Director
666.00
--
Ms. Teri L. Lawver
Ms. Teri L. Lawver
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
33.37K
-2.26%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
11.14%
Kynam Capital Management LP
9.19%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.95%
The Vanguard Group, Inc.
5.93%
Other
60.89%
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
11.14%
Kynam Capital Management LP
9.19%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.95%
The Vanguard Group, Inc.
5.93%
Other
60.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.58%
Hedge Fund
32.92%
Investment Advisor/Hedge Fund
31.28%
Venture Capital
3.61%
Research Firm
2.78%
Pension Fund
0.39%
Bank and Trust
0.36%
Individual Investor
0.27%
Insurance Company
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
420
73.66M
110.92%
-14.44M
2025Q2
422
75.86M
114.26%
-13.90M
2025Q1
437
75.31M
113.46%
-13.68M
2024Q4
437
75.05M
113.05%
-8.14M
2024Q3
429
73.28M
110.59%
-7.16M
2024Q2
432
71.48M
107.86%
-10.62M
2024Q1
419
71.32M
108.50%
+952.72K
2023Q4
406
62.72M
112.33%
-412.93K
2023Q3
403
52.10M
110.18%
-8.63M
2023Q2
410
51.84M
109.57%
-7.47M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wellington Management Company, LLP
5.23M
7.88%
-3.12M
-37.37%
Jun 30, 2025
Kynam Capital Management LP
6.10M
9.19%
-399.27K
-6.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.59M
6.91%
-38.52K
-0.83%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.95M
5.95%
+62.97K
+1.62%
Jun 30, 2025
The Vanguard Group, Inc.
3.94M
5.94%
+56.45K
+1.45%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.75M
5.65%
+398.14K
+11.88%
Jun 30, 2025
Commodore Capital LP
3.45M
5.2%
+100.00K
+2.99%
Jun 30, 2025
Bellevue Asset Management AG
3.31M
4.98%
+235.95K
+7.68%
Jun 30, 2025
Point72 Asset Management, L.P.
2.80M
4.22%
+180.55K
+6.89%
Jun 30, 2025
State Street Investment Management (US)
2.41M
3.62%
-400.86K
-14.28%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Propel Opportunities ETF
3.32%
ALPS Medical Breakthroughs ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
SPDR S&P Biotech ETF
0.65%
Direxion Daily S&P Biotech Bull 3X Shares
0.34%
Avantis US Small Cap Equity ETF
0.15%
First Trust Small Cap Growth AlphaDEX Fund
0.14%
Nuveen ESG Small-Cap ETF
0.14%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
T Rowe Price Small-Mid Cap ETF
0.12%
View more
Simplify Propel Opportunities ETF
Proportion3.32%
ALPS Medical Breakthroughs ETF
Proportion1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.92%
SPDR S&P Biotech ETF
Proportion0.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.34%
Avantis US Small Cap Equity ETF
Proportion0.15%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.14%
Nuveen ESG Small-Cap ETF
Proportion0.14%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.13%
T Rowe Price Small-Mid Cap ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
